NextCure Inc

NXTC

Company Profile

  • Business description

    NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.

  • Contact

    9000 Virginia Manor Road
    Suite 200
    BeltsvilleMD20705
    USA

    T: +1 240 399-4900

    https://www.nextcure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    43

Stocks News & Analysis

stocks

Plunge in ASX share unwarranted

Weak result distracts from improving trading and cost outlook.
stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,057.6048.70-0.53%
CAC 407,826.3545.67-0.58%
DAX 4023,559.5751.76-0.22%
Dow JONES (US)46,292.7888.76-0.19%
FTSE 1009,209.4413.88-0.15%
HKSE26,518.65359.531.37%
NASDAQ22,573.47215.50-0.95%
Nikkei 22545,630.31136.650.30%
NZX 50 Index13,181.3144.770.34%
S&P 5006,656.9236.83-0.55%
S&P/ASX 2008,764.5050.50-0.57%
SSE Composite Index3,853.6431.810.83%

Market Movers